Pulmonary arteriovenous malformations (PAVMs) often occur in children with
hereditary hemorrhagic telangiectasia (HHT). A 14-year longitudinal study of
PAVMs in children with HHT was undertaken to assess the prevalence, the clinical
impact, and progression of these malformations. This was a retrospective,
single-center study from May 2002 to December 2016 of 129 children with HHT
diagnosed using Curacao criteria and/or confirmed by genetic testing.
Transthoracic contrast echocardiography (TTCE) was the primary screening
modality in all patients and PAVMs were diagnosed based on Barzilai criteria.
Moderately positive TTCE (Barzilai criteria ≥ 2) was confirmed with subsequent
contrast chest CT. New PAVMs were diagnosed with a positive TTCE after an
initial negative TTCE. Embolization of PAVMs were performed according to HHT
consensus guidelines. Of 129 children with HHT, 76 (59%) were found to have
PAVMs. Sixty-seven (88%) were positive for PAVMs on initial screening. Of 63
children without PAVMs on initial screening, 31 were followed for >1 year.
Nine of the 31 (29%) developed new PAVMs after initial negative study.
Thirty-eight (50%) of the total 76 children with PAVMs had or developed lesions
large enough to be treated with embolization. Nine patients with PAVMs initially
too small to be treated with embolization, developed progression of disease and
ultimately were treated with embolization over time. The majority, 60% (23/38),
of the children with large PAVMs had no related clinical symptoms. After
embolization, 21% (8/38), of patients underwent repeat interventions. Genetic
diagnosis, age, and gender were not associated with risk of having PAVM nor with
need for repeat interventions. Nearly 60% of children with HHT develop PAVMs.
The risk for new PAVMs to develop, small PAVMs to become large, and previously
embolized PAVMs to require further intervention remains throughout childhood.
Thus, children with HHT require continued follow-up until adulthood.